<HTML>
<HEAD>
<TITLE>Filed by Bowne Pure Compliance</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): February 24, 2009</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>eResearchTechnology, Inc.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>0-29100</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>22-3264604</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>1818 Market Street, Philadelphia, PA<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>19103</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>215-972-0420</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>&nbsp;</B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt"><B>ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS;
COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.</B>


<P align="left" style="font-size: 10pt"><B>Executive Compensation</B>


<P align="left" style="font-size: 10pt">At meetings held on February&nbsp;24 and 26, 2009, our Board of Directors (the &#147;Board&#148;), at the recommendation of its
Compensation Committee (the &#147;Committee&#148;), took the following actions with respect to the 2009 compensation for our
named executive officers:

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>2009 Bonus</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>2009 Car</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Stock</B> </TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Executive Officer</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009 Salary</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Opportunity</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B> Allowance</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Options</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD align="center">Michael J. McKelvey, Ph.D.<BR>
President and Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">515,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">386,250</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">12,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">225,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center">Joel Morganroth, M.D.<BR>
Chairman and Chief Scientific Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">202,757</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">101,378</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">12,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">70,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD align="center">Keith D. Schneck<BR>
Executive Vice President and Chief Financial
Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">298,700</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">149,350</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">9,240</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">75,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center">Jeffrey Litwin, M.D.<BR>
Executive Vice President and Chief Medical Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">281,190</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">210,595</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">9,240</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD align="center">Robert S. Brown<BR>
Senior Vice President, Strategic Marketing,
Planning &#038; Partnerships</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">249,312</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">124,656</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">9,240</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40,000</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="left" style="font-size: 10pt"><B>2009 Bonus Plan</B>


<P align="left" style="font-size: 10pt">At those meetings, the Board, at the recommendation of the Committee, also approved the 2009 Bonus Plan (the &#147;2009
Plan&#148;). The 2009 Plan was effective beginning on January&nbsp;1, 2009 and will remain effective for fiscal year 2009. The
purpose of the 2009 Plan is to promote the interests of the Company and its stockholders by providing employees with
financial rewards upon achievement of specified business objectives, as well as help us attract and retain employees by
providing attractive compensation opportunities linked to performance results. All of our employees are eligible to
participate in the 2009 Plan, subject in some cases to certain waiting periods and with the exception that certain
sales personnel participate in a separate commission incentive plan instead of the 2009 Plan.


<P align="left" style="font-size: 10pt">Bonuses payable under the 2009 Plan are recommended by the Committee and presented to the Board. Bonuses payable to
eligible participants are based on a variety of factors, including both objective and subjective criteria. The
objective criteria consist of targets for revenue, net income, the revenue projected to be generated by new contracts
into which we enter regardless of when we actually recognize the revenue (the &#147;Contract Revenues&#148;) and gross profits of
our ERT consulting group, defined as revenue less direct payments made to providers of consulting services (the
&#147;Consulting Profits&#148;).


<P align="left" style="font-size: 10pt">For Dr.&nbsp;McKelvey and Messrs.&nbsp;Schneck and Brown, 15% of the bonus will be based on the extent to which we achieve
specified revenue targets, 45% will be based on the extent to which we achieve specified net income targets and the
remaining 40% will be based on individual performance objectives. For Dr.&nbsp;Morganroth, 30% of the bonus will be based
on the extent to which we achieve specified revenue targets and the remaining 70% will be based on the extent to which
we achieve specified net income targets. For Dr.&nbsp;Litwin, $140,595 of his bonus opportunity will be allocated as
follows: 15% of the bonus will be based on the extent to which we achieve specified revenue targets, 40% will be based
on the extent to which we achieve specified net income targets, 20% will be based on the extent to which we achieve
specified Contract Revenues targets and the remaining 25% will be based on individual performance objectives. The
remaining $70,000 of Dr.&nbsp;Litwin&#146;s bonus opportunity will be payable based on our Consulting Profits.


<P align="left" style="font-size: 10pt">The revenue and net income targets at which bonus plan participants would earn 100% of the bonus opportunity
attributable to those targets is slightly higher than the upper end of the range for revenues and net income provided
as guidance for 2009 in the Company&#146;s press release issued on February&nbsp;26, 2009. In the current economic climate, the
Board intends that the plan participants earn the full bonus opportunity with respect to those targets only if the
Company achieves superior performance notwithstanding current economic conditions.

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt">Dr.&nbsp;McKelvey&#146;s individual goals focus on executing key initiatives supporting our 2009 business plan, including
reviewing and making recommendations regarding potential expansion opportunities, growing our electronic patient
reporting outcome business, implementing programs to increase centralization of ECGs in clinical trials and executing
plans to enhance our information technology infrastructure. Mr.&nbsp;Schneck&#146;s individual goals consist primarily of
enhancing the tax efficiency and cash flow of our operations, improving investor relations, implementing improvements
to our billing systems and finance/accounting expenses and continuing to improve our planning and forecasting
processes. Dr.&nbsp;Litwin&#146;s individual goals focus on continuing to improve our quality audit and management systems,
participating in our expanded sales and marketing initiatives by representing the Company at meetings, conferences and
similar events and improving the profitability of our consulting group. Mr.&nbsp;Brown&#146;s individual goals focus on
development of strategic partnerships or similar relationships with specified entities or in specific industries or
geographic regions.


<P align="left" style="font-size: 10pt">Our named executive officers will be eligible to receive 50% to 150% of the 2009 bonus opportunity noted in the table
above that is allocable to each objective target category, based on the extent to which we achieve the various specified targets,
with the exception that Dr.&nbsp;Litwin&#146;s bonus for Consulting Profits shall be calculated at 10% of Consulting Profits and
shall not exceed the $70,000 bonus opportunity applicable to that
target. Amounts payable based on achievement of individual
performance objectives can range from 0-100% of the applicable bonus
opportunity.


<P align="left" style="font-size: 10pt">Bonuses are payable based on the extent to which annual targets have been achieved, with the bonuses (if any) normally
being paid within ninety (90)&nbsp;days after the end of the calendar year in which the bonuses were earned. Bonuses
normally will be paid in cash in a single lump sum, subject to payroll taxes and tax withholdings, as applicable.


<P align="left" style="font-size: 10pt">Notwithstanding the foregoing, the Committee retains the discretion under the 2009 Plan to adjust the amount of any
bonus to be paid, regardless of whether or the extent to which any of the objective criteria, including revenue, net
income, Contract Revenues and Consulting Profits targets, are achieved.


<P align="left" style="font-size: 10pt"><B>Stock Options</B>


<P align="left" style="font-size: 10pt">The stock options were granted on March&nbsp;2, 2009, the second business day following the release of our annual 2008
financial results, with an exercise price of $4.60 per share, the closing price of our common stock on the date of
the grant. The options will vest in four equal consecutive annual installments commencing one year from the date of
grant.


<P align="left" style="font-size: 10pt"><B>SIGNATURES</B>


<P align="left" style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" colspan="3"><B>eResearchTechnology, Inc.</B></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" colspan="3"><B>(Registrant)</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date: March&nbsp;2, 2009
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Keith Schneck</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD nowrap colspan="2" align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Keith Schneck</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Executive Vice President and Chief
Financial Officer</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3




</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c81920e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 18688}]
{"company-data": {"conformed-name": "ERESEARCHTECHNOLOGY INC /DE/", "cik": "0001026650", "assigned-sic": "8734", "irs-number": "223264604", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-29100", "film-number": "09647922"}, "business-address": {"street1": "30 SOUTH 17TH STREET", "city": "PHILADELPHIA", "state": "PA", "zip": "19103", "phone": "2159720420"}, "mail-address": {"street1": "30 SOUTH 17TH STREET", "city": "PHILADELPHIA", "state": "PA", "zip": "19102"}, "former-company": {"former-conformed-name": "PREMIER RESEARCH WORLDWIDE LTD", "date-changed": "19961107"}}
Filed by Bowne Pure Compliance
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 24, 2009
eResearchTechnology, Inc.
(Exact name of registrant as specified in its charter)
Delaware
0-29100
22-3264604
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
1818 Market Street, Philadelphia, PA
19103
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
215-972-0420
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS;
COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
Executive Compensation
At meetings held on February 24 and 26, 2009, our Board of Directors (the "Board"), at the recommendation of its
Compensation Committee (the "Committee"), took the following actions with respect to the 2009 compensation for our
named executive officers:
2009 Bonus
2009 Car
Stock
Executive Officer
2009 Salary
Opportunity
Allowance
Options
Michael J. McKelvey, Ph.D.
President and Chief Executive Officer
$
515,000
$
386,250
$
12,000
225,000
Joel Morganroth, M.D.
Chairman and Chief Scientific Officer
$
202,757
$
101,378
$
12,000
70,000
Keith D. Schneck
Executive Vice President and Chief Financial
Officer
$
298,700
$
149,350
$
9,240
75,000
Jeffrey Litwin, M.D.
Executive Vice President and Chief Medical Officer
$
281,190
$
210,595
$
9,240
50,000
Robert S. Brown
Senior Vice President, Strategic Marketing,
Planning & Partnerships
$
249,312
$
124,656
$
9,240
40,000
2009 Bonus Plan
At those meetings, the Board, at the recommendation of the Committee, also approved the 2009 Bonus Plan (the "2009
Plan"). The 2009 Plan was effective beginning on January 1, 2009 and will remain effective for fiscal year 2009. The
purpose of the 2009 Plan is to promote the interests of the Company and its stockholders by providing employees with
financial rewards upon achievement of specified business objectives, as well as help us attract and retain employees by
providing attractive compensation opportunities linked to performance results. All of our employees are eligible to
participate in the 2009 Plan, subject in some cases to certain waiting periods and with the exception that certain
sales personnel participate in a separate commission incentive plan instead of the 2009 Plan.
Bonuses payable under the 2009 Plan are recommended by the Committee and presented to the Board. Bonuses payable to
eligible participants are based on a variety of factors, including both objective and subjective criteria. The
objective criteria consist of targets for revenue, net income, the revenue projected to be generated by new contracts
into which we enter regardless of when we actually recognize the revenue (the "Contract Revenues") and gross profits of
our ERT consulting group, defined as revenue less direct payments made to providers of consulting services (the
"Consulting Profits").
For Dr. McKelvey and Messrs. Schneck and Brown, 15% of the bonus will be based on the extent to which we achieve
specified revenue targets, 45% will be based on the extent to which we achieve specified net income targets and the
remaining 40% will be based on individual performance objectives. For Dr. Morganroth, 30% of the bonus will be based
on the extent to which we achieve specified revenue targets and the remaining 70% will be based on the extent to which
we achieve specified net income targets. For Dr. Litwin, $140,595 of his bonus opportunity will be allocated as
follows: 15% of the bonus will be based on the extent to which we achieve specified revenue targets, 40% will be based
on the extent to which we achieve specified net income targets, 20% will be based on the extent to which we achieve
specified Contract Revenues targets and the remaining 25% will be based on individual performance objectives. The
remaining $70,000 of Dr. Litwin's bonus opportunity will be payable based on our Consulting Profits.
The revenue and net income targets at which bonus plan participants would earn 100% of the bonus opportunity
attributable to those targets is slightly higher than the upper end of the range for revenues and net income provided
as guidance for 2009 in the Company's press release issued on February 26, 2009. In the current economic climate, the
Board intends that the plan participants earn the full bonus opportunity with respect to those targets only if the
Company achieves superior performance notwithstanding current economic conditions.
Dr. McKelvey's individual goals focus on executing key initiatives supporting our 2009 business plan, including
reviewing and making recommendations regarding potential expansion opportunities, growing our electronic patient
reporting outcome business, implementing programs to increase centralization of ECGs in clinical trials and executing
plans to enhance our information technology infrastructure. Mr. Schneck's individual goals consist primarily of
enhancing the tax efficiency and cash flow of our operations, improving investor relations, implementing improvements
to our billing systems and finance/accounting expenses and continuing to improve our planning and forecasting
processes. Dr. Litwin's individual goals focus on continuing to improve our quality audit and management systems,
participating in our expanded sales and marketing initiatives by representing the Company at meetings, conferences and
similar events and improving the profitability of our consulting group. Mr. Brown's individual goals focus on
development of strategic partnerships or similar relationships with specified entities or in specific industries or
geographic regions.
Our named executive officers will be eligible to receive 50% to 150% of the 2009 bonus opportunity noted in the table
above that is allocable to each objective target category, based on the extent to which we achieve the various specified targets,
with the exception that Dr. Litwin's bonus for Consulting Profits shall be calculated at 10% of Consulting Profits and
shall not exceed the $70,000 bonus opportunity applicable to that
target. Amounts payable based on achievement of individual
performance objectives can range from 0-100% of the applicable bonus
opportunity.
Bonuses are payable based on the extent to which annual targets have been achieved, with the bonuses (if any) normally
being paid within ninety (90) days after the end of the calendar year in which the bonuses were earned. Bonuses
normally will be paid in cash in a single lump sum, subject to payroll taxes and tax withholdings, as applicable.
Notwithstanding the foregoing, the Committee retains the discretion under the 2009 Plan to adjust the amount of any
bonus to be paid, regardless of whether or the extent to which any of the objective criteria, including revenue, net
income, Contract Revenues and Consulting Profits targets, are achieved.
Stock Options
The stock options were granted on March 2, 2009, the second business day following the release of our annual 2008
financial results, with an exercise price of $4.60 per share, the closing price of our common stock on the date of
the grant. The options will vest in four equal consecutive annual installments commencing one year from the date of
grant.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
eResearchTechnology, Inc.
(Registrant)
Date: March 2, 2009
By:
/s/ Keith Schneck
Keith Schneck
Executive Vice President and Chief
Financial Officer